secwatch.observer — SEC 8-K summary
======================================

Issuer:     Vivani Medical, Inc. (VANI)
CIK:        0001266806
Form:       8-K
Filed at:   2025-08-13T23:59:59+00:00
Accession:  0001753926-25-001328
Event type: earnings
Sentiment:  positive
Materiality: 0.80
Item codes: 1.01, 2.02, 3.02, 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Vivani Medical raises $10M, reports Q2 loss of $7.1M, advances semaglutide implant NPM-139
--------------------------------------------------------------------------------

- Raised $10M via private placement of 7.94M shares at $1.26/share with director-affiliated entity.
- Q2 2025 net loss $7.1M vs $5.3M in Q2 2024; cash $8.1M as of June 30, 2025.
- Positive preclinical data for NPM-139: ~20% weight loss maintained >6 months with single implant.
- Plans to initiate NPM-139 clinical program in 2026; spin off Cortigent division in H2 2025.
- Appointed Anthony Baldor as CFO; additional $21.25M committed capital through July 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1266806/000175392625001328/0001753926-25-001328-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1266806/000175392625001328/vani-20250811.htm
  HTML page:      https://secwatch.observer/filing/0001753926-25-001328

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer